3-(4-(methylsulfonyl)phenylamino)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carboxamide

ID: ALA3782012

Chembl Id: CHEMBL3782012

PubChem CID: 127030133

Max Phase: Preclinical

Molecular Formula: C16H20N4O4S

Molecular Weight: 364.43

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CS(=O)(=O)c1ccc(Nc2nn(C3CCOCC3)cc2C(N)=O)cc1

Standard InChI:  InChI=1S/C16H20N4O4S/c1-25(22,23)13-4-2-11(3-5-13)18-16-14(15(17)21)10-20(19-16)12-6-8-24-9-7-12/h2-5,10,12H,6-9H2,1H3,(H2,17,21)(H,18,19)

Standard InChI Key:  GUZHLPAZMODXTH-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA3782012

    ---

Associated Targets(Human)

JAK1 Tclin Tyrosine-protein kinase JAK1 (8569 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TYK2 Tclin Tyrosine-protein kinase TYK2 (5029 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
JAK3 Tclin Tyrosine-protein kinase JAK3 (8349 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
JAK2 Tclin Tyrosine-protein kinase JAK2 (12915 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 364.43Molecular Weight (Monoisotopic): 364.1205AlogP: 1.48#Rotatable Bonds: 5
Polar Surface Area: 116.31Molecular Species: NEUTRALHBA: 7HBD: 2
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 12.24CX Basic pKa: 1.96CX LogP: 1.39CX LogD: 1.39
Aromatic Rings: 2Heavy Atoms: 25QED Weighted: 0.83Np Likeness Score: -1.42

References

1. Simov V, Deshmukh SV, Dinsmore CJ, Elwood F, Fernandez RB, Garcia Y, Gibeau C, Gunaydin H, Jung J, Katz JD, Kraybill B, Lapointe B, Patel SB, Siu T, Su H, Young JR..  (2016)  Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.,  26  (7): [PMID:26927423] [10.1016/j.bmcl.2016.02.035]

Source